Victoza is Novo Nordisk’s once-daily injectable GLP-1 agonist and made around $3.6 billion in sales last year, making it the top-selling drug in the category.

The GLP-1 liraglutide showed potential benefit in reducing stroke recurrence and improving functional outcomes after minor ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Novo Nordisk is actively defending its older diabetes medication, Victoza. This week, the company submitted a citizen petition to the U.S. Food and Drug Association (FDA) requesting that the FDA ...

Danish pharmaceutical company Novo Nordisk A/S (NOVO-B.KO) said Wednesday its drug Victoza has been shown in a clinical study to be more efficient than a competing drug in improving diabetes ...

Novo Nordisk A/S (NOVO-B.KO) expects its closely-watched diabetes treatment Victoza to reach European customers in the nearest future, Chief Scientific Officer Mads Krogsgaard Thomsen said in an ...

Liraglutide, also owned by Novo Nordisk®, is the world's 3 rd most popular glucagon-like peptide-1 ("GLP-1") or glucose-dependent insulinotropic ("GIP") weight loss/diabetes drug on the market today.

Fewer than 20,000 monthly prescriptions were written for liraglutide (Saxenda, Novo Nordisk) from October 2023 until the end of the study and for naltrexone/bupropion (Contrave, Orexigen ...

Novo Nordisk sells the drug semaglutide under the brands Ozempic for diabetes and Wegovy for weight loss. The company's older weight loss drug, liraglutide, is marketed as Victoza for diabetes and ...